Compare NYMX to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 4.54 |
|---|---|
| Trade Time: | Nov 25 |
| Change: | |
| Prev Close: | 4.57 |
| Open: | 4.58 |
| Bid: | 3.79 x 100 |
| Ask: | 5.30 x 300 |
| 1y Target Est: | N/A |
| Day's Range: | 4.42 - 4.59 |
|---|---|
| 52wk Range: | 2.20 - 7.07 |
| Volume: | 52,600 |
| Avg Vol (3m): | 76,122.7 |
| Market Cap: | 139.73M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.15 |
| Div & Yield: | N/A (N/A) |
| Mon, Nov 23 | Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company's BPH Drug NX-1207GlobeNewswire |
| Fri, Nov 13 | Nymox Reports Third Quarter 2009 Financial ResultsGlobeNewswire |
| Fri, Nov 13 | Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution NetworksWall Street Transcript |
| Wed, Oct 14 | Nymox's NX-1207 to be Clinically Tested for Prostate CancerGlobeNewswire |
| Mon, Oct 5 | Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPHGlobeNewswire |
| Wed, Aug 26 | Nymox's NX-1207 Shows Major Effect On Liver CancerGlobeNewswire |
| Fri, Aug 14 | Nymox Reports Second Quarter 2009 Financial ResultsGlobeNewswire |
| Wed, Jun 24 | 9 Stocks to Shake the Marketat Motley Fool |
| Tue, Jun 2 | Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPHGlobeNewswire |
| Fri, May 15 | Nymox Reports First Quarter 2009 Financial ResultsGlobeNewswire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.